Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) | PAR 18 530

Opportunity Information: Apply for PAR 18 530

The NIH grant opportunity "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)" (PAR-18-530) is designed to push promising scientific and engineering advances beyond early proof-of-concept and into practical tools that researchers, clinicians, and other end users can realistically deploy. The core idea is translation: taking a technology, method, assay, device, or system that has shown feasibility and advancing it through the kinds of refinement, optimization, and validation work needed to make it genuinely useful in real pre-clinical, clinical, or other applied settings. The FOA is meant to support work that improves the ability to understand disease biology and pathology, as well as work that strengthens applied capabilities such as risk assessment, detection, prevention, diagnosis, treatment, management, and monitoring of disease status, as long as the topic fits within the missions of the participating NIH institutes.

A defining feature of this FOA is the required partnership structure. Applications are expected to be submitted by an interdisciplinary, multi-institutional team operating in a strategic alliance, explicitly combining at least one academic organization and at least one industrial organization. The purpose of this structure is to bridge common gaps that slow translation, such as differences in technical expertise, development experience, manufacturing or design controls knowledge, validation practices, and understanding of user needs and real-world workflows. The partnership is expected to function as a coordinated development team with a coherent plan, not as loosely connected collaborators. Applicants are expected to plan, design, and validate their solution with a strong focus on suitability for end users, meaning the technology should be shaped around who will use it, in what environment, and under what constraints (for example, clinical workflow, laboratory throughput, operating conditions, usability, reliability, and performance expectations).

In practical terms, the NIH is looking for proposals that move a solution from "it can work" to "it is ready to be used in the intended setting." The FOA specifically allows budgets to support activities such as enhancing or adapting an existing approach, optimizing performance, establishing robustness and reproducibility, and validating performance in relevant environments. The announcement frames "innovation" in a pragmatic way: innovation is not only novelty on paper, but the likelihood of delivering a new capability that end users can actually benefit from. That emphasis signals that reviewers will likely care about development milestones, clear performance metrics, validation plans, and credible pathways to adoption in the chosen setting.

Clinical trials are optional under this R01, but they are allowed when they directly support translation. In this context, supported clinical trials would generally be those that test functionality or validate performance of the tool or method in the intended real-world setting. At the same time, the FOA draws a clear boundary around what it is not trying to fund. It is not meant to support commercial-scale production, exploratory basic research that is not tied to a translational endpoint, or conventional clinical trials where translation of a technology is not the primary driver. In other words, even if a study involves humans, it should be anchored in maturing and validating a technology or method, rather than being a stand-alone therapeutic efficacy trial with no central technology-development component.

Eligibility is broad and includes many organization types across the public, private, and nonprofit sectors. Eligible applicants include state, county, and local governments; special districts; independent school districts; public and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and other entities. The FOA also highlights additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), along with faith-based or community-based organizations, regional organizations, U.S. territories or possessions, federal agencies, and non-U.S. (foreign) organizations.

Administratively, this is an NIH discretionary grant using the R01 mechanism, with clinical trial participation labeled as optional depending on the project needs. The opportunity is associated with CFDA numbers 93.286, 93.394, 93.395, and 93.847, and it was created on 2017-12-21. The source listing notes an original closing date of 2021-03-25, which is important for applicants to verify in the current NIH notices and the active FOA record, since NIH opportunities can be reissued, updated, or replaced over time. Overall, the FOA is best understood as a development-focused translational program: it rewards teams that can combine academic discovery strength with industrial development discipline to deliver validated, user-ready diagnostic or treatment-related technologies that measurably improve research or care capabilities.

• The National Institutes of Health in the education, food and nutrition, health sector is offering a public funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.286, 93.394, 93.395, 93.847.
• This funding opportunity was created on 2017-12-21.
• Applicants must submit their applications by 2021-03-25. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 18 530

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: